Ensysce Biosciences (NASDAQ:ENSC) Releases Quarterly Earnings Results, Misses Estimates By $0.16 EPS

Ensysce Biosciences (NASDAQ:ENSC) released its earnings results on Monday. The company reported ($2.90) EPS for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.16), Zacks reports. Ensysce Biosciences had a negative return on equity of 292.81% and a negative net margin of 179.26%.

Ensysce Biosciences Stock Down 3.8 %

Shares of ENSC traded down $0.19 during trading hours on Monday, reaching $4.83. 15,575 shares of the company traded hands, compared to its average volume of 507,711. The stock has a market capitalization of $6.31 million, a P/E ratio of -0.18 and a beta of 0.64. The business has a fifty day moving average price of $6.68 and a 200-day moving average price of $6.55. Ensysce Biosciences has a 12-month low of $2.12 and a 12-month high of $14.67.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.